ECSP23077322A - Derivados de fósforo como nuevos inhibidores de sos1 - Google Patents

Derivados de fósforo como nuevos inhibidores de sos1

Info

Publication number
ECSP23077322A
ECSP23077322A ECSENADI202377322A ECDI202377322A ECSP23077322A EC SP23077322 A ECSP23077322 A EC SP23077322A EC SENADI202377322 A ECSENADI202377322 A EC SENADI202377322A EC DI202377322 A ECDI202377322 A EC DI202377322A EC SP23077322 A ECSP23077322 A EC SP23077322A
Authority
EC
Ecuador
Prior art keywords
compounds
new
phosphorus derivatives
sos1
preparation
Prior art date
Application number
ECSENADI202377322A
Other languages
English (en)
Inventor
Jeremie Xavier G Mortier
Jens SCHRÖDER
Atanas Marinov Kamburov
Keith Graham
Gerhard Siemeister
Michael Erkelenz
Roman Hillig
Benjamin Bader
Timo Stellfeld
Christoph Philipp Hethey
Matthias Arlt
Felix Pape
Steffen Gressies
Katrin Nowak-Reppel
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of ECSP23077322A publication Critical patent/ECSP23077322A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6568—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
    • C07F9/65685—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms the ring phosphorus atom being part of a phosphine oxide or thioxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención abarca los derivados de fósforo de la fórmula general (I): [IMAGEN ADJUNTA], en donde R1, R2, R3, R4, R5, R6, X1, X2, X3, X4 e Y son como se definen en el presente documento, métodos de preparación de dichos compuestos, compuestos intermedios útiles para la preparación de dichos compuestos, composiciones farmacéuticas y combinaciones que comprenden dichos compuestos y el uso de dichos compuestos para la fabricación de composiciones farmacéuticas para el tratamiento o profilaxis de enfermedades, en particular de trastornos hiperproliferativos, especialmente enfermedades asociadas a SOS1, como agente único o en combinación con otros ingredientes activos.
ECSENADI202377322A 2021-04-14 2023-10-12 Derivados de fósforo como nuevos inhibidores de sos1 ECSP23077322A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21168256.2A EP4074317A1 (en) 2021-04-14 2021-04-14 Phosphorus derivatives as novel sos1 inhibitors

Publications (1)

Publication Number Publication Date
ECSP23077322A true ECSP23077322A (es) 2023-11-30

Family

ID=75529812

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202377322A ECSP23077322A (es) 2021-04-14 2023-10-12 Derivados de fósforo como nuevos inhibidores de sos1

Country Status (22)

Country Link
US (1) US20240247015A1 (es)
EP (2) EP4074317A1 (es)
JP (1) JP2024513595A (es)
KR (1) KR20230170032A (es)
CN (1) CN117500507A (es)
AR (1) AR125672A1 (es)
AU (1) AU2022258751A1 (es)
BR (1) BR112023019030A2 (es)
CA (1) CA3216503A1 (es)
CL (1) CL2023003045A1 (es)
CO (1) CO2023013469A2 (es)
CR (1) CR20230485A (es)
DO (1) DOP2023000218A (es)
EC (1) ECSP23077322A (es)
GE (1) GEAP202316387A (es)
IL (1) IL307448A (es)
JO (1) JOP20230252A1 (es)
MX (1) MX2023012187A (es)
PE (1) PE20240022A1 (es)
PH (1) PH12023552869A1 (es)
TW (1) TW202304467A (es)
WO (1) WO2022219035A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4148056A4 (en) * 2020-05-09 2024-05-29 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. SOS1 INHIBITOR CONTAINING PHOSPHORUS
US20230357239A1 (en) * 2020-09-18 2023-11-09 Bayer Aktiengesellschaft Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitors
CN114716478A (zh) * 2021-01-07 2022-07-08 武汉人福创新药物研发中心有限公司 6-取代磷酰基喹唑啉类衍生物及其制备方法和用途
WO2023134374A1 (zh) * 2022-01-12 2023-07-20 如东凌达生物医药科技有限公司 一类嘧啶并杂环类化合物、制备方法和用途
WO2024056782A1 (en) * 2022-09-16 2024-03-21 Bayer Aktiengesellschaft Sulfone-substituted pyrido[3,4-d]pyrimidine derivatives for the treatment of cancer
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
CN121487951A (zh) 2023-04-07 2026-02-06 锐新医药公司 大环ras抑制剂
AU2024251341A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
EP4695261A1 (en) 2023-04-14 2026-02-18 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
TW202610639A (zh) 2024-08-09 2026-03-16 德商拜耳廠股份有限公司 Sos-1抑制劑之鹽

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2015A (en) 1841-03-26 Improvement in rotary steam-engines
IL89027A (en) 1988-01-29 1993-01-31 Lilly Co Eli Quinazoline derivatives, process for their preparation and fungicidal, insecticidal and miticidal compositions containing them
IL89028A0 (en) 1988-01-29 1989-08-15 Lilly Co Eli Quinoline,quinazoline and cinnoline derivatives
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US5236925A (en) 1991-10-24 1993-08-17 American Home Products Corporation Fused pyrimidines as angiotensin II antagonists
JP2001514173A (ja) 1997-08-25 2001-09-11 バイエル・コーポレーシヨン Ｎｐｙｙ５アンタゴニストとしての複素環式ケトン
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2004058267A1 (en) * 2002-12-23 2004-07-15 Ariad Pharmaceuticals, Inc. Heterocycles and uses thereof
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
WO2005005382A2 (en) 2003-07-02 2005-01-20 Cytokinetics, Inc. Compounds, compositions and methods
US7452893B2 (en) 2003-08-15 2008-11-18 Merck & Co., Inc. 4-cycloakylaminopyrazolo pyrimidine NMDA/NR2B antagonists
MXPA06012333A (es) 2004-04-30 2007-01-17 Takeda Pharmaceutical Compuesto de amida heterociclico y uso del mismo como un inhibidor mmp-13.
SE0401540D0 (sv) 2004-06-15 2004-06-15 Astrazeneca Ab New compounds
ITMI20042042A1 (it) 2004-10-26 2005-01-26 Pharmeste Srl Derivati solfonammidici antagonisti del recettore dei vanilloidi trpv1
EP2581440B1 (en) 2005-06-08 2016-03-16 The University of North Carolina At Chapel Hill Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics
WO2007134986A1 (en) 2006-05-23 2007-11-29 F. Hoffmann-La Roche Ag Pyridopyrimidinone derivatives
US8536168B2 (en) 2007-03-15 2013-09-17 Novartis Ag Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway
JP2008280341A (ja) 2007-04-12 2008-11-20 Sumitomo Chemical Co Ltd ヒドラジド化合物およびその防除用途
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
FR2929615B1 (fr) 2008-04-02 2010-12-17 Tfchem Composes c-aryl glycosides pour le traitement du diabete et de l'obesite.
JP2011523646A (ja) 2008-05-21 2011-08-18 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのリン誘導体
US8163763B2 (en) 2008-07-31 2012-04-24 Genentech, Inc. Pyrimidine compounds, compositions and methods of use
NZ591793A (en) 2008-08-27 2012-11-30 Takeda Pharmaceutical Substituted 1-(4-fluoro-5-(2-fluoropyridin-3-yl)-1-((pyrindin-2-yl)sulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine compounds
CA2752885A1 (en) 2009-02-27 2010-09-02 Ambit Biosciences Corporation Jak kinase modulating quinazoline derivatives and methods of use thereof
US8461164B2 (en) 2009-08-31 2013-06-11 Dow Agrosciences, Llc. Pteridines and their use as agrochemicals
EP2473487B1 (en) 2009-09-03 2016-10-26 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
EP2611789A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
WO2012030918A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Adenosine a3 receptor modulating compounds and methods of use thereof
US20130225578A1 (en) 2010-09-01 2013-08-29 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
BR112013005223A2 (pt) 2010-09-03 2016-05-03 Bayer Ip Gmbh "pirimidinonas e dihidropirimidinonas fusionadas substituídas."
CA2815131C (en) 2010-10-20 2020-06-09 Gruenenthal Gmbh Substituted 6-amino-nicotinamides as kcnq2/3 modulators
WO2012066122A1 (en) 2010-11-18 2012-05-24 Syngenta Participations Ag 2 - (pyridin- 2 -yl) -quinazoline derivatives and their use as microbicides
AR084217A1 (es) 2010-12-10 2013-05-02 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
CN102584828B (zh) 2011-01-14 2016-01-27 上海艾力斯医药科技有限公司 吡咯烷[3，4-d]嘧啶衍生物、制备方法及其应用
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
CN102911172A (zh) 2011-08-04 2013-02-06 上海恒瑞医药有限公司 杂芳基并嘧啶类衍生物、其制备方法和用途
WO2013030138A1 (en) 2011-09-01 2013-03-07 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
CN103387490B (zh) 2012-05-09 2015-08-26 中国科学院兰州化学物理研究所 一种甲苯羰化合成苯乙酸的方法
IN2014MN02652A (es) 2012-06-08 2015-08-21 Gilead Sciences Inc
WO2014100501A1 (en) 2012-12-20 2014-06-26 Sanford-Burnham Medical Research Institute Small molecule agonists of neurotensin receptor 1
EA201591291A1 (ru) 2013-01-08 2015-12-30 Савира Фармасьютикалз Гмбх Производные пиримидона и их применение в лечении, облегчении или профилактике вирусного заболевания
WO2014153666A1 (en) 2013-03-29 2014-10-02 Vida Therapeutics, Inc. Indoline compounds as granzyme b inhibitors
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
EA031601B1 (ru) 2013-07-31 2019-01-31 Джилид Сайэнс, Инк. Ингибиторы syk
WO2015155306A1 (en) 2014-04-11 2015-10-15 Almirall, S.A. New trpa1 antagonists
MX2017002775A (es) 2014-09-15 2017-08-10 Rugen Holdings (Cayman) Ltd Derivados de pirrolopirimidina como antagonistas del receptor de n-metil-d-aspartato (nmda), subunidad nr2b.
SG11201702147TA (en) 2014-09-17 2017-04-27 Celgene Quanticel Res Inc Histone demethylase inhibitors
US20180271869A1 (en) 2014-09-22 2018-09-27 Jie Liu Treatment of anxiety disorders and autism spectrum disorders
CN104803954B (zh) 2015-04-30 2018-01-26 上海应用技术学院 一种福沙那韦中间体的制备方法
DK3319939T3 (da) 2015-07-08 2025-02-24 Cv6 Therapeutics Ni Ltd Hydantoin indeholdende deoxyuridintriphosphatase-inhibitorer
EP3372601B1 (en) 2015-10-22 2022-09-21 Mitsubishi Tanabe Pharma Corporation Novel bicyclic heterocyclic compound
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
EP3558979B1 (en) * 2016-12-22 2021-02-17 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
GB201700814D0 (en) 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
CA3056970A1 (en) 2017-03-21 2018-09-27 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
FR3066761B1 (fr) 2017-05-23 2020-10-30 Centre Nat Rech Scient Nouveaux composes inhibiteurs des canaux ioniques
PL3728254T3 (pl) 2017-12-21 2023-06-12 Boehringer Ingelheim International Gmbh Benzyloaminopodstawione pirydopirymidynony i pochodne jako inhibitory sos1
WO2019173182A1 (en) 2018-03-05 2019-09-12 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists
CN109776607B (zh) 2019-02-21 2021-06-04 青岛海洋生物医药研究院 芳基磷氧类和芳基磷硫类化合物及其制备方法和应用
US20230096028A1 (en) 2019-03-01 2023-03-30 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
EP4148056A4 (en) * 2020-05-09 2024-05-29 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. SOS1 INHIBITOR CONTAINING PHOSPHORUS

Also Published As

Publication number Publication date
JOP20230252A1 (ar) 2023-10-12
EP4074317A1 (en) 2022-10-19
KR20230170032A (ko) 2023-12-18
DOP2023000218A (es) 2023-11-15
PE20240022A1 (es) 2024-01-04
AR125672A1 (es) 2023-08-02
CO2023013469A2 (es) 2024-04-29
GEAP202316387A (en) 2023-12-25
JP2024513595A (ja) 2024-03-26
WO2022219035A1 (en) 2022-10-20
BR112023019030A2 (pt) 2023-10-24
EP4322962A1 (en) 2024-02-21
IL307448A (en) 2023-12-01
CR20230485A (es) 2023-12-12
US20240247015A1 (en) 2024-07-25
TW202304467A (zh) 2023-02-01
CN117500507A (zh) 2024-02-02
AU2022258751A1 (en) 2023-10-05
MX2023012187A (es) 2023-10-25
CL2023003045A1 (es) 2024-03-22
CA3216503A1 (en) 2022-10-20
PH12023552869A1 (en) 2024-05-20

Similar Documents

Publication Publication Date Title
CO2023013469A2 (es) Derivados de fósforo como nuevos inhibidores de sos1
CO2018010966A2 (es) Nuevos derivados de pirazolopirimidina
CL2021001042A1 (es) Nuevos compuestos antihelmínticos
JOP20220131A1 (ar) مركبات أمينو كينولون تحمل بدائل تستخدم كمثبطات لـ dgkalpha من أجل تنشيط المناعة
DOP2019000206A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
CO2019004137A2 (es) 1,2,4–triazolonas 2,4,5–trisustituidas
ECSP20008441A (es) Dihidrooxadiazinonas
DOP2020000023A (es) Nuevos derivados de quinolina
CO2020013876A2 (es) Nuevos derivados de quinolina
CU23366B7 (es) Oxazolidinonas substituidas para terapia de combinación
UY29803A1 (es) Derivados de adeninas, composiciones farmacéuticas conteniéndolos, procedimientos de preparación y aplicaciones
DOP2019000275A (es) Nuevos derivados de pirazol bicíclicos
MX2022001803A (es) [1,2,4]triazolo[1,5-c]quinazolin-5-aminas.
UY38816A (es) Nuevos derivados de isoquinolina
UY37971A (es) Derivados de indol macrocíclicos sustituidos
UY37973A (es) Derivados de indol macrocíclicos
UY37972A (es) Derivados de indol macrocíclicos sustituidos con cloro
CL2024000710A1 (es) Nuevos derivados de quinolina
CL2025002072A1 (es) Inhibidores de prmt5–mta.
DOP2024000096A (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno